Abstract
Patient was a 60-year-old male presented with palpitation. He had background history of diabetes type 2, obstructive sleep apnea on CPAP and hypertension.
He was diagnosed with Primary central nervous system diffuse large B cell lymphoma 2 years ago. He received high-dose methotrexate, radiotherapy and currently on treatment with Ibrutinib 560 mg.
ECG showed atrial fibrillation with heart rate 66 bpm and Premature ventricular contractions (PVCs). He had normal myocardial perfusion scan. Echocardiogram showed normal LV size and systolic function, ejection fraction of 55% and no hemodynamically significant valve disease. Patient was started on amiodarone 200 mg daily and underwent successful electrical cardioversion and remained in normal sinus rhythm.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–40.
Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129:2581–4.
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491–500.
Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–805.
https://www.ccs.ca/images/Guidelines/Guidelines_POS_Library/2018%20AF%20Update_Supplement_Final.pdf
Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17:31–37.e13.
Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1:772–8.
Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma. 2016;57:2914–6.
IMBRUVICA Prescribing Information (www.imbruvica.com). January 2019. https://www.imbruvica.com/files/prescribing-information.pdf. Accessed 12 Dec 2019.
Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58:1630–9.
Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991–5.
Madgula AS, Singh M, Almnajam M, Pickett CC, Kim AS. Ventricular tachycardia storm in a patient treated with ibrutinib for waldenstrom macroglobulinemia. J Am Coll Cardiol CardioOncol. 2020;2(3):523–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Ibrutinib and Cardiac Arrythmias. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)